Establishment Labs to Present at TD Cowen's 45th Annual Health Care Conference
Establishment Labs Holdings (NASDAQ: ESTA), a global medical technology company focused on women's health in breast aesthetics and reconstruction, has announced its participation in TD Cowen's 45th Annual Health Care Conference. Founder and CEO Juan José Chacón-Quirós and CFO Raj Denhoy will present in a fireside chat on March 4, 2025 at 2:30 p.m. ET.
The presentation will be available via live webcast on the company's investor relations website, with archived versions accessible afterward. Establishment Labs offers solutions for breast health, aesthetics, and reconstruction in over 90 countries, having delivered more than four million Motiva devices since 2010.
The company's portfolio includes minimally invasive platforms such as Mia Femtech, Preservé, GEM (currently in pivotal study), Motiva Flora tissue expander, and Zensor RFID technology with the Zenº biosensor. These innovations are supported by over 200 patent applications and 100+ scientific studies, with manufacturing conducted at two FDA-compliant facilities in Costa Rica.
Establishment Labs Holdings (NASDAQ: ESTA), un'azienda globale di tecnologia medica focalizzata sulla salute delle donne nell'estetica e ricostruzione mammaria, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen. Il fondatore e CEO Juan José Chacón-Quirós e il CFO Raj Denhoy parteciperanno a una chiacchierata informale il 4 marzo 2025 alle 14:30 ET.
La presentazione sarà disponibile tramite webcast dal vivo sul sito web delle relazioni con gli investitori dell'azienda, con versioni archiviate accessibili in seguito. Establishment Labs offre soluzioni per la salute mammaria, estetica e ricostruzione in oltre 90 paesi, avendo fornito più di quattro milioni di dispositivi Motiva dal 2010.
Il portafoglio dell'azienda include piattaforme minimamente invasive come Mia Femtech, Preservé, GEM (attualmente in studio cruciale), espansore tissutale Motiva Flora e tecnologia RFID Zensor con il biosensore Zenº. Queste innovazioni sono supportate da oltre 200 domande di brevetto e più di 100 studi scientifici, con produzione condotta in due strutture conformi alla FDA in Costa Rica.
Establishment Labs Holdings (NASDAQ: ESTA), una empresa global de tecnología médica centrada en la salud de la mujer en estética y reconstrucción mamaria, ha anunciado su participación en la 45ª Conferencia Anual de Salud de TD Cowen. El fundador y CEO Juan José Chacón-Quirós y el CFO Raj Denhoy presentarán en una charla informal el 4 de marzo de 2025 a las 2:30 p.m. ET.
La presentación estará disponible a través de una transmisión en vivo en el sitio web de relaciones con inversionistas de la empresa, con versiones archivadas accesibles después. Establishment Labs ofrece soluciones para la salud mamaria, estética y reconstrucción en más de 90 países, habiendo entregado más de cuatro millones de dispositivos Motiva desde 2010.
El portafolio de la empresa incluye plataformas mínimamente invasivas como Mia Femtech, Preservé, GEM (actualmente en estudio pivotal), expansor de tejido Motiva Flora y tecnología RFID Zensor con el biosensor Zenº. Estas innovaciones están respaldadas por más de 200 solicitudes de patentes y más de 100 estudios científicos, con fabricación realizada en dos instalaciones conformes a la FDA en Costa Rica.
Establishment Labs Holdings (NASDAQ: ESTA)는 여성 건강, 특히 유방 미용 및 재건에 중점을 둔 글로벌 의료 기술 회사로, TD Cowen의 제45회 연례 건강 관리 컨퍼런스에 참여한다고 발표했습니다. 창립자이자 CEO인 Juan José Chacón-Quirós와 CFO인 Raj Denhoy는 2025년 3월 4일 오후 2:30 ET에 화상 대화에 참여할 예정입니다.
프레젠테이션은 회사의 투자자 관계 웹사이트를 통해 실시간 웹캐스트로 제공되며, 이후 아카이브된 버전도 접근 가능합니다. Establishment Labs는 2010년 이후로 400만 개 이상의 Motiva 장치를 제공하며, 90개국 이상에서 유방 건강, 미용 및 재건 솔루션을 제공합니다.
회사의 포트폴리오는 Mia Femtech, Preservé, GEM(현재 중요한 연구 중), Motiva Flora 조직 확장기 및 Zenº 바이오센서를 갖춘 Zensor RFID 기술과 같은 최소 침습 플랫폼을 포함합니다. 이러한 혁신은 200건 이상의 특허 출원과 100건 이상의 과학 연구에 의해 지원되며, 코스타리카의 두 개의 FDA 준수 시설에서 제조됩니다.
Establishment Labs Holdings (NASDAQ: ESTA), une entreprise mondiale de technologie médicale axée sur la santé des femmes dans l'esthétique et la reconstruction mammaire, a annoncé sa participation à la 45e Conférence Annuelle sur la Santé de TD Cowen. Le fondateur et PDG Juan José Chacón-Quirós et le directeur financier Raj Denhoy participeront à une discussion informelle le 4 mars 2025 à 14h30 ET.
La présentation sera disponible en direct via un webinaire sur le site Web des relations avec les investisseurs de l'entreprise, avec des versions archivées accessibles par la suite. Establishment Labs propose des solutions pour la santé mammaire, l'esthétique et la reconstruction dans plus de 90 pays, ayant livré plus de quatre millions de dispositifs Motiva depuis 2010.
Le portefeuille de l'entreprise comprend des plateformes peu invasives telles que Mia Femtech, Preservé, GEM (actuellement en étude décisive), l'expanseur tissulaire Motiva Flora et la technologie RFID Zensor avec le biosenseur Zenº. Ces innovations sont soutenues par plus de 200 demandes de brevet et plus de 100 études scientifiques, avec une fabrication réalisée dans deux installations conformes à la FDA au Costa Rica.
Establishment Labs Holdings (NASDAQ: ESTA), ein globales Medizintechnikunternehmen, das sich auf die Gesundheit von Frauen in der Brustästhetik und -rekonstruktion konzentriert, hat seine Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen angekündigt. Gründer und CEO Juan José Chacón-Quirós und CFO Raj Denhoy werden am 4. März 2025 um 14:30 Uhr ET in einem informellen Gespräch präsentieren.
Die Präsentation wird über einen Live-Webcast auf der Investor-Relations-Website des Unternehmens verfügbar sein, mit archivierten Versionen, die danach zugänglich sind. Establishment Labs bietet Lösungen für Brustgesundheit, Ästhetik und Rekonstruktion in über 90 Ländern an und hat seit 2010 mehr als vier Millionen Motiva-Geräte geliefert.
Das Portfolio des Unternehmens umfasst minimal-invasive Plattformen wie Mia Femtech, Preservé, GEM (derzeit in entscheidender Studie), Motiva Flora Gewebeexpander und Zensor RFID-Technologie mit dem Zenº Biosensor. Diese Innovationen werden durch über 200 Patentanmeldungen und mehr als 100 wissenschaftliche Studien unterstützt, wobei die Produktion in zwei FDA-konformen Einrichtungen in Costa Rica erfolgt.
- Establishment Labs continues to expand its presence in healthcare conferences, potentially increasing investor visibility
- The company has delivered over 4 million Motiva devices since 2010, demonstrating strong market adoption
- ESTA has a diverse portfolio of innovative products spanning breast aesthetics, reconstruction, and minimally invasive procedures
- The company has a strong intellectual property position with over 200 patent applications
- Products are available in over 90 countries, indicating significant global market penetration
- The press release doesn't mention any financial performance metrics or guidance
- Some key products like GEM and Zenº are still in clinical trials, not yet generating revenue
- No mention of competitive positioning or market share in the breast aesthetics industry
- The press release doesn't address any regulatory challenges or approval timelines
- No information about the company's growth strategy or upcoming product launches
Juan José Chacón-Quirós, Founder and Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, are scheduled to present in a fireside chat on Tuesday, March 4, 2025 at 2:30 p.m. ET.
A live webcast of the presentation will be available on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/. Archived versions of the webcasts will be available on the same website following the completion of the events.
About Establishment Labs
Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women’s health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The Company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 90 countries. With over four million Motiva ® devices delivered to plastic and reconstructive surgeons since 2010, the Company’s products have created a new standard for safety and patient satisfaction. The company’s minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for breast augmentation, revision augmentation and mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company’s first biosensor Zenº™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patents applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250225554885/en/
Investor/Media Contact:
Raj Denhoy
415 828-1044
rdenhoy@establishmentlabs.com
Source: Establishment Labs Holdings Inc.
FAQ
When will Establishment Labs (ESTA) present at TD Cowen's Health Care Conference?
How many Motiva devices has ESTA delivered to surgeons since 2010?
What are the main products in Establishment Labs' (ESTA) portfolio?
In how many countries are Establishment Labs' (ESTA) products available?
What is the current status of ESTA's GEM and Zenº products?
How many patents and scientific studies support Establishment Labs' (ESTA) technologies?
